eClinical Solutions Market by Product (CDMS, EDC, CTMS, eCOA, Analytics, RTMS, eTMF, Safety), Delivery Mode (On-Demand, On-premise, Cloud-based), Clinical Trial Phases, End User (Pharma/Biopharma Companies, CROs, Hospitals) - Global Forecast to 2022
“eClinical Solutions Market by Product (CDMS, EDC, CTMS, eCOA, Analytics, RTMS, eTMF, Safety), Delivery Mode (On-Demand, On-premise, Cloud-based), Clinical Trial Phases, End User (Pharma/Biopharma Companies, CROs, Hospitals) - Global Forecast to 2022”
The global eClinical solutions market is estimated to reach 7.61 billionby 2022, at a high CAGR of 12.4% in the forecast period (2017-2022). The growth of the global eClinical solutions market is driven by factors such as a need for improved data standardization and an increase in R&D expenditure by pharma-biotech companies with significant IT budgets for drug development. In addition, the rising number of clinical trials, especially across emerging countries in the Asia-Pacific region, offers growth opportunities for vendors of eClinical solutions. However, a dearth of skilled research professionals and concerns over patient data privacy are hampering the adoption of these solutions.
On the basis of clinical trial phases, the global eClinical solutions market is divided into phase I, phase II, phase III, and phase IV. The phase III clinical trials segment accounted for the largest share of the global eClinical solutions market in 2016. In addition, the phase III clinical trials segment is expected to grow at the highest CAGR during the forecast period.
Geographically, North America commanded the largest share of the global eClinical solutions market in 2016, followed by Europe. The large market share of North America is attributed to the significant number of ongoing clinical trials in this region. A number of factors such as the increasing government grants to support clinical trials, continuous product development and launch by eClinical solution vendors, growth in the number of partnerships for new drug development, high prevalence of lifestyle diseases, and an increasing aging population are further stimulating the demand for eClinical solutions in North America. However, strict and lengthy government requirements and high cost of conducting trials are negatively affecting the growth of the market in this region.
Although developed regions such as North America and Europe held large shares in the eClinical solutions market in 2016, it is the Asia-Pacific region that is poised to achieve the highest CAGR in the next five years. Factors such as the increasing outsourcing of clinical trial studies by large pharma and biopharma companies to Asia-Pacific countries, the presence of large patient population, and the low operating cost of conducting clinical trials are propelling the growth of the eClinical solutions market in this region.
The eClinical solutions market is highly competitive, with a large number of global and local players. Oracle Corporation (U.S.) Medidata Solutions, Inc. (U.S.), and PAREXEL International Corporation (U.S.) were the top three players in the eClinical solutions market in 2016. Partnerships, agreements, and collaborations; product launches, enhancements, and deployments; mergers and acquisitions; and geographic expansions are the major strategies adopted by most players to achieve growth in the eClinical solutions market.
Research Coverage:
The report covers software solutions used across all phases in the clinical trial process. It aims at estimating the market size and future growth potential of this market across different segments such as product type, delivery mode, clinical trial phase, end user, and regions. The report also includes an in-depth competitive analysis of the key players with their company profiles, recent developments, and key market strategies.
Reasons to Buy the Report:
This report focuses on various levels of analysis—market share analysis of the top players and company profiles, which discuss basic views on the competitive landscape; emerging and high-growth segments of the eClinical solutions market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help them garner greater market shares. Companies purchasing the report could use any one of the combination of the strategies mentioned below, namely, market penetration, product development/innovation, market development, market diversification, and competitive assessment to strengthen their market shares.
The report provides insights on the following pointers:
The global eClinical solutions market is estimated to reach 7.61 billionby 2022, at a high CAGR of 12.4% in the forecast period (2017-2022). The growth of the global eClinical solutions market is driven by factors such as a need for improved data standardization and an increase in R&D expenditure by pharma-biotech companies with significant IT budgets for drug development. In addition, the rising number of clinical trials, especially across emerging countries in the Asia-Pacific region, offers growth opportunities for vendors of eClinical solutions. However, a dearth of skilled research professionals and concerns over patient data privacy are hampering the adoption of these solutions.
On the basis of clinical trial phases, the global eClinical solutions market is divided into phase I, phase II, phase III, and phase IV. The phase III clinical trials segment accounted for the largest share of the global eClinical solutions market in 2016. In addition, the phase III clinical trials segment is expected to grow at the highest CAGR during the forecast period.
Geographically, North America commanded the largest share of the global eClinical solutions market in 2016, followed by Europe. The large market share of North America is attributed to the significant number of ongoing clinical trials in this region. A number of factors such as the increasing government grants to support clinical trials, continuous product development and launch by eClinical solution vendors, growth in the number of partnerships for new drug development, high prevalence of lifestyle diseases, and an increasing aging population are further stimulating the demand for eClinical solutions in North America. However, strict and lengthy government requirements and high cost of conducting trials are negatively affecting the growth of the market in this region.
Although developed regions such as North America and Europe held large shares in the eClinical solutions market in 2016, it is the Asia-Pacific region that is poised to achieve the highest CAGR in the next five years. Factors such as the increasing outsourcing of clinical trial studies by large pharma and biopharma companies to Asia-Pacific countries, the presence of large patient population, and the low operating cost of conducting clinical trials are propelling the growth of the eClinical solutions market in this region.
The eClinical solutions market is highly competitive, with a large number of global and local players. Oracle Corporation (U.S.) Medidata Solutions, Inc. (U.S.), and PAREXEL International Corporation (U.S.) were the top three players in the eClinical solutions market in 2016. Partnerships, agreements, and collaborations; product launches, enhancements, and deployments; mergers and acquisitions; and geographic expansions are the major strategies adopted by most players to achieve growth in the eClinical solutions market.
Research Coverage:
The report covers software solutions used across all phases in the clinical trial process. It aims at estimating the market size and future growth potential of this market across different segments such as product type, delivery mode, clinical trial phase, end user, and regions. The report also includes an in-depth competitive analysis of the key players with their company profiles, recent developments, and key market strategies.
Reasons to Buy the Report:
This report focuses on various levels of analysis—market share analysis of the top players and company profiles, which discuss basic views on the competitive landscape; emerging and high-growth segments of the eClinical solutions market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help them garner greater market shares. Companies purchasing the report could use any one of the combination of the strategies mentioned below, namely, market penetration, product development/innovation, market development, market diversification, and competitive assessment to strengthen their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on eClinical solutions offered by the top 10 players in the market. The report analyzes the eClinical solutions market, by product, delivery mode, clinical trial phase, and end users across four geographies.
- Product Development/Innovation: Detailed insights on current technologies, research and development activities, and product launches in the eClinical solutions market.
- Market Development: Comprehensive information of lucrative emerging markets. The report analyzes the markets for various eClinical solutions across four geographies (North America, Europe, Asia-Pacific, and the Rest of the World).
- Competitive Assessment: Assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the eClinical solutions market.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MAJOR MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1.1 Bottom-up approach
2.2.1.2 Top-down approach
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ECLINICAL SOLUTIONS: MARKET OVERVIEW
4.2 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2015 VS. 2017 VS. 2022 (USD MILLION)
4.3 REGIONAL ANALYSIS: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE (2016)
4.4 ECLINICAL SOLUTIONS MARKET SHARE, BY CLINICAL TRIAL PHASE (2017 VS. 2022)
4.5 REGIONAL ANALYSIS: ECLINICAL SOLUTIONS MARKET, BY END USER (2017–2022)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MAJOR MARKET DRIVERS
5.2.1.1 Increasing operational costs and regulatory requirements associated with clinical research studies
5.2.1.2 Growing adoption of novel software solutions in clinical research
5.2.1.3 Rising government funding & grants to support clinical trials
5.2.1.4 Growing adoption of eClinical solutions for improved data standardization
5.2.1.5 Increasing R&D expenditure by pharma-biotech companies with augmented IT expenditure allocations for drug development pipeline
5.2.1.6 Growing customer base for eClinical solutions
5.2.2 MAJOR MARKET RESTRAINTS
5.2.2.1 High implementation costs associated with eClinical solutions
5.2.2.2 Dearth of skilled professionals for operating eClinical solutions
5.2.2.3 Limited awareness among researchers related to advantages of eClinical solutions
5.2.3 KEY GROWTH OPPORTUNITIES
5.2.3.1 Increasing clinical research activities in emerging Asian countries
5.2.3.2 Increased outsourcing of clinical trial processes by industrial researchers to CROs
5.2.3.3 Rising number of clinical trials, especially across emerging countries
5.2.3.4 Shift from manual data interpretation to real-time data analysis during clinical studies
5.2.4 MAJOR MARKET CHALLENGES
5.2.4.1 Limited adoption of eClinical solutions in developing nations
5.2.4.2 Software reliability
5.2.4.3 Patient privacy
6 GLOBAL ECLINICAL SOLUTIONS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS
6.3 CLINICAL TRIAL MANAGEMENT SYSTEMS
6.4 CLINICAL ANALYTICS PLATFORMS
6.5 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT
6.6 CLINICAL DATA INTEGRATION PLATFORMS
6.7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS
6.8 SAFETY SOLUTIONS
6.9 ELECTRONIC TRIAL MASTER FILE SYSTEMS
6.10 REGULATORY INFORMATION MANAGEMENT SOLUTIONS
6.11 OTHER ECLINICAL SOLUTIONS
7 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE
7.1 INTRODUCTION
7.2 WEB-HOSTED (ON-DEMAND) SOLUTIONS
7.3 LICENSED ENTERPRISE (ON-PREMISE) SOLUTIONS
7.4 CLOUD-BASED (SAAS) SOLUTIONS
8 GLOBAL ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
8.1 INTRODUCTION
8.2 PHASE I CLINICAL TRIALS
8.3 PHASE II CLINICAL TRIALS
8.4 PHASE III CLINICAL TRIALS
8.5 PHASE IV CLINICAL TRIALS
9 ECLINICAL SOLUTIONS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.4 CONSULTING SERVICE COMPANIES
9.5 MEDICAL DEVICE MANUFACTURERS
9.6 HOSPITALS
9.7 ACADEMIC RESEARCH INSTITUTES
10 ECLINICAL SOLUTIONS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA-PACIFIC
10.5 REST OF THE WORLD
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
11.3.2 PRODUCT DEPLOYMENTS
11.3.3 PRODUCT LAUNCHES & PRODUCT ENHANCEMENTS
11.3.4 MERGERS & ACQUISITIONS
11.3.5 EXPANSIONS
11.3.6 OTHER STRATEGIES
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments)*
12.1 INTRODUCTION
12.2 ORACLE CORPORATION
12.3 MEDIDATA SOLUTIONS, INC.
12.4 PAREXEL INTERNATIONAL CORPORATION
12.5 BIOCLINICA, INC. (A SUBSIDIARY OF CINVEN)
12.6 DATATRAK INTERNATIONAL, INC.
12.7 CRF HEALTH
12.8 ERT CLINICAL
12.9 MERGE HEALTHCARE INCORPORATED
12.10 OMNICOMM SYSTEMS, INC.
12.11 MAXISIT INC.
12.12 BIO-OPTRONICS, INC.
12.13 ECLINICAL SOLUTIONS, LLC.
*Business Overview, Products Offered, Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE*
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MAJOR MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1.1 Bottom-up approach
2.2.1.2 Top-down approach
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ECLINICAL SOLUTIONS: MARKET OVERVIEW
4.2 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2015 VS. 2017 VS. 2022 (USD MILLION)
4.3 REGIONAL ANALYSIS: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE (2016)
4.4 ECLINICAL SOLUTIONS MARKET SHARE, BY CLINICAL TRIAL PHASE (2017 VS. 2022)
4.5 REGIONAL ANALYSIS: ECLINICAL SOLUTIONS MARKET, BY END USER (2017–2022)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MAJOR MARKET DRIVERS
5.2.1.1 Increasing operational costs and regulatory requirements associated with clinical research studies
5.2.1.2 Growing adoption of novel software solutions in clinical research
5.2.1.3 Rising government funding & grants to support clinical trials
5.2.1.4 Growing adoption of eClinical solutions for improved data standardization
5.2.1.5 Increasing R&D expenditure by pharma-biotech companies with augmented IT expenditure allocations for drug development pipeline
5.2.1.6 Growing customer base for eClinical solutions
5.2.2 MAJOR MARKET RESTRAINTS
5.2.2.1 High implementation costs associated with eClinical solutions
5.2.2.2 Dearth of skilled professionals for operating eClinical solutions
5.2.2.3 Limited awareness among researchers related to advantages of eClinical solutions
5.2.3 KEY GROWTH OPPORTUNITIES
5.2.3.1 Increasing clinical research activities in emerging Asian countries
5.2.3.2 Increased outsourcing of clinical trial processes by industrial researchers to CROs
5.2.3.3 Rising number of clinical trials, especially across emerging countries
5.2.3.4 Shift from manual data interpretation to real-time data analysis during clinical studies
5.2.4 MAJOR MARKET CHALLENGES
5.2.4.1 Limited adoption of eClinical solutions in developing nations
5.2.4.2 Software reliability
5.2.4.3 Patient privacy
6 GLOBAL ECLINICAL SOLUTIONS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS
6.3 CLINICAL TRIAL MANAGEMENT SYSTEMS
6.4 CLINICAL ANALYTICS PLATFORMS
6.5 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT
6.6 CLINICAL DATA INTEGRATION PLATFORMS
6.7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS
6.8 SAFETY SOLUTIONS
6.9 ELECTRONIC TRIAL MASTER FILE SYSTEMS
6.10 REGULATORY INFORMATION MANAGEMENT SOLUTIONS
6.11 OTHER ECLINICAL SOLUTIONS
7 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE
7.1 INTRODUCTION
7.2 WEB-HOSTED (ON-DEMAND) SOLUTIONS
7.3 LICENSED ENTERPRISE (ON-PREMISE) SOLUTIONS
7.4 CLOUD-BASED (SAAS) SOLUTIONS
8 GLOBAL ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
8.1 INTRODUCTION
8.2 PHASE I CLINICAL TRIALS
8.3 PHASE II CLINICAL TRIALS
8.4 PHASE III CLINICAL TRIALS
8.5 PHASE IV CLINICAL TRIALS
9 ECLINICAL SOLUTIONS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.4 CONSULTING SERVICE COMPANIES
9.5 MEDICAL DEVICE MANUFACTURERS
9.6 HOSPITALS
9.7 ACADEMIC RESEARCH INSTITUTES
10 ECLINICAL SOLUTIONS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA-PACIFIC
10.5 REST OF THE WORLD
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
11.3.2 PRODUCT DEPLOYMENTS
11.3.3 PRODUCT LAUNCHES & PRODUCT ENHANCEMENTS
11.3.4 MERGERS & ACQUISITIONS
11.3.5 EXPANSIONS
11.3.6 OTHER STRATEGIES
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments)*
12.1 INTRODUCTION
12.2 ORACLE CORPORATION
12.3 MEDIDATA SOLUTIONS, INC.
12.4 PAREXEL INTERNATIONAL CORPORATION
12.5 BIOCLINICA, INC. (A SUBSIDIARY OF CINVEN)
12.6 DATATRAK INTERNATIONAL, INC.
12.7 CRF HEALTH
12.8 ERT CLINICAL
12.9 MERGE HEALTHCARE INCORPORATED
12.10 OMNICOMM SYSTEMS, INC.
12.11 MAXISIT INC.
12.12 BIO-OPTRONICS, INC.
12.13 ECLINICAL SOLUTIONS, LLC.
*Business Overview, Products Offered, Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE*
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
LIST OF TABLES
Table 1 U.S.: INDICATIVE LIST OF LIFE SCIENCE STARTUPS LAUNCHED BETWEEN 2011 & 2015
Table 2 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 3 GLOBAL ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 4 NORTH AMERICA: ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 5 GLOBAL CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 6 NORTH AMERICA: CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 7 GLOBAL CLINICAL ANALYTICS PLATFORMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 8 NORTH AMERICA: CLINICAL ANALYTICS PLATFORMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 9 GLOBAL RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 10 NORTH AMERICA: RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 GLOBAL CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 12 NORTH AMERICA: CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 13 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 14 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 15 GLOBAL SAFETY SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 16 NORTH AMERICA: SAFETY SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 17 GLOBAL ELECTRONIC TRIAL MASTER FILE SYSTEMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 18 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 19 GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 20 NORTH AMERICA: GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE ,BY COUNTRY, 2015–2022 (USD MILLION)
Table 21 GLOBAL OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 22 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY MODE OF DELIVERY, 2015–2022 (USD MILLION)
Table 24 WEB-HOSTED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 25 LICENSED ENTERPRISE ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 26 CLOUD-BASED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 27 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 28 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE I CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 29 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE II CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 31 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 32 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE III CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 33 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 34 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE IV CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 35 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 36 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 37 ECLINICAL SOLUTIONS MARKET SIZE FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2015–2022 (USD MILLION)
Table 38 KEY STRATEGIC ALLIANCES BETWEEN CROS AND PHARMA COMPANIES (2011–2015)
Table 39 ECLINICAL SOLUTIONS MARKET SIZE FOR CROS, BY REGION, 2015–2022 (USD MILLION)
Table 40 ECLINICAL SOLUTIONS MARKET SIZE FOR CONSULTING SERVICE COMPANIES, BY REGION, 2015–2022 (USD MILLION)
Table 41 ECLINICAL SOLUTIONS MARKET SIZE FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2015–2022 (USD MILLION)
Table 42 ECLINICAL SOLUTIONS MARKET SIZE FOR HOSPITALS, BY REGION, 2015–2022 (USD MILLION)
Table 43 ECLINICAL SOLUTIONS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2015–2022 (USD MILLION)
Table 44 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 45 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
Table 46 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015-2022 (USD MILLION)
Table 47 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015-2022 (USD MILLION)
Table 48 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015-2022 (USD MILLION)
Table 49 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
Table 50 U.S.: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015-2022 (USD MILLION)
Table 51 U.S.: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015-2022 (USD MILLION)
Table 52 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015-2022 (USD MILLION)
Table 53 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015-2022 (USD MILLION)
Table 54 EMA-APPROVED BIOSIMILARS
Table 55 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 56 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2022 (USD MILLION)
Table 57 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 58 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 59 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 60 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2022 (USD MILLION)
Table 61 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 62 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 63 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 64 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2022 (USD MILLION)
Table 65 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 66 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 67 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2013–2017)
Table 68 PRODUCT DEPLOYMENTS (2013–2017)
Table 69 PRODUCT LAUNCHES & PRODUCT ENHANCEMENTS (2013–2017)
Table 70 MERGERS & ACQUISITIONS (2013–2017)
Table 71 EXPANSIONS (2013–2017)
Table 72 OTHER STRATEGIES (2013–2017)
Table 1 U.S.: INDICATIVE LIST OF LIFE SCIENCE STARTUPS LAUNCHED BETWEEN 2011 & 2015
Table 2 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 3 GLOBAL ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 4 NORTH AMERICA: ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 5 GLOBAL CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 6 NORTH AMERICA: CLINICAL TRIAL MANAGEMENT SYSTEMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 7 GLOBAL CLINICAL ANALYTICS PLATFORMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 8 NORTH AMERICA: CLINICAL ANALYTICS PLATFORMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 9 GLOBAL RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 10 NORTH AMERICA: RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 GLOBAL CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 12 NORTH AMERICA: CLINICAL DATA INTEGRATION PLATFORMS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 13 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 14 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 15 GLOBAL SAFETY SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 16 NORTH AMERICA: SAFETY SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 17 GLOBAL ELECTRONIC TRIAL MASTER FILE SYSTEMS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 18 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 19 GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 20 NORTH AMERICA: GLOBAL REGULATORY INFORMATION MANAGEMENT SOLUTIONS (RIMS) MARKET SIZE ,BY COUNTRY, 2015–2022 (USD MILLION)
Table 21 GLOBAL OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 22 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY MODE OF DELIVERY, 2015–2022 (USD MILLION)
Table 24 WEB-HOSTED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 25 LICENSED ENTERPRISE ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 26 CLOUD-BASED ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 27 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 28 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE I CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 29 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE II CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 31 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 32 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE III CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 33 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 34 ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE IV CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 35 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 36 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 37 ECLINICAL SOLUTIONS MARKET SIZE FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2015–2022 (USD MILLION)
Table 38 KEY STRATEGIC ALLIANCES BETWEEN CROS AND PHARMA COMPANIES (2011–2015)
Table 39 ECLINICAL SOLUTIONS MARKET SIZE FOR CROS, BY REGION, 2015–2022 (USD MILLION)
Table 40 ECLINICAL SOLUTIONS MARKET SIZE FOR CONSULTING SERVICE COMPANIES, BY REGION, 2015–2022 (USD MILLION)
Table 41 ECLINICAL SOLUTIONS MARKET SIZE FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2015–2022 (USD MILLION)
Table 42 ECLINICAL SOLUTIONS MARKET SIZE FOR HOSPITALS, BY REGION, 2015–2022 (USD MILLION)
Table 43 ECLINICAL SOLUTIONS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2015–2022 (USD MILLION)
Table 44 GLOBAL ECLINICAL SOLUTIONS MARKET SIZE, BY REGION, 2015–2022 (USD MILLION)
Table 45 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
Table 46 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015-2022 (USD MILLION)
Table 47 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015-2022 (USD MILLION)
Table 48 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015-2022 (USD MILLION)
Table 49 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
Table 50 U.S.: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015-2022 (USD MILLION)
Table 51 U.S.: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015-2022 (USD MILLION)
Table 52 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015-2022 (USD MILLION)
Table 53 CANADA: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015-2022 (USD MILLION)
Table 54 EMA-APPROVED BIOSIMILARS
Table 55 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 56 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2022 (USD MILLION)
Table 57 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 58 EUROPE: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 59 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 60 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2022 (USD MILLION)
Table 61 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 62 ASIA-PACIFIC: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 63 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY PRODUCT, 2015–2022 (USD MILLION)
Table 64 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY DELIVERY MODE, 2015–2022 (USD MILLION)
Table 65 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY CLINICAL TRIAL PHASE, 2015–2022 (USD MILLION)
Table 66 ROW: ECLINICAL SOLUTIONS MARKET SIZE, BY END USER, 2015–2022 (USD MILLION)
Table 67 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2013–2017)
Table 68 PRODUCT DEPLOYMENTS (2013–2017)
Table 69 PRODUCT LAUNCHES & PRODUCT ENHANCEMENTS (2013–2017)
Table 70 MERGERS & ACQUISITIONS (2013–2017)
Table 71 EXPANSIONS (2013–2017)
Table 72 OTHER STRATEGIES (2013–2017)
Over the years, endoscopy has evolved significantly and is widely used for the diagnosis and treatment of various disorders like cancer, GERD, and obesity, among others. In the past few years, the market has witnessed significant technological advancements, as companies have introduced new endoscopy and camera systems. This has aided in the diagnosis and treatment of diseases. This report covers the definition, description, and forecast of the global endoscopy market in terms of endoscopes, visualization systems, accessories, and by the applications for these instruments.
The global endoscopy market was valued at $xx billion in 2013 and is expected to reach $xx billion by 2018, at a CAGR of xx%. Growth in patient preference for minimally invasive surgeries and the presence of a favorable reimbursement environment in selected countries are the major factors driving the growth of this market. Moreover, various government bodies have extended their help in the form of investments, funds, and grants, which has stimulated the usage of advanced endoscopy systems.
Growth in the endoscopy market is driven by Asian countries like China, India, and Japan as well as countries like Australia, New Zealand, and UAE. The global endoscopy market is broadly segmented into four product categories, namely, endoscopes, visualization systems, other instruments, and accessories. In 2013, the endoscopes market accounted for the largest share—around xx%—of the global endoscopy market, by segment. This market was valued at $xx billion in 2013 and is expected to reach $xx billion by 2018, at a CAGR of xx% from 2013 to 2018. The visualization systems market closely followed the endoscopes market and is expected to grow at a CAGR of xx% to reach $xx billion by 2018 from $xx billion in 2013. The growth of this market is likely to be driven by the rising incidences of cancer and increasing preference for minimally invasive surgeries, particularly for capsule endoscopes.
Visualization systems form an integral part of an endoscopic instrument. The market for visualization systems is segmented into endoscopy cameras, video processors, video convertors, camera heads, light sources, wireless displays and monitors, transmitters and receivers, and others. The wireless displays and monitors segment held the largest share of the visualization systems market. This segment is also expected to grow at the highest CAGR of xx% from 2013 to 2018, to reach $xx billion by 2018.
The endoscopy market is dominated by Ethicon (Johnson & Johnson) (U.S.), Olympus Corporation (Japan), Covidien Pic (Ireland), Karl Storz GmbH (Germany), Boston Scientific, Inc. (U.S.), and Stryker Corporation (Japan). These players jointly accounted for -xx% of the overall market share. Cook Medical Incorporated (U.S.), Hoya Corporation (Pentax Medical System) (Japan), Fujifilm Holding Corporation (Fujinon) (Japan), Richard Wolf GmbH (Germany), Smith and Nephew, Inc. (U.S.), and Conmed Corporation (U.S.) are some of the other prominent players in the global endoscopy market.
